In addition to being a disease that manifests itself with chronic anovulation, menstrual irregularities and hyperandrogenism, Polycystic ovary syndrome (PCOS) can also exhibit its character with metabolic abnormalities. Obesity seen in the majority of PCOS patients is the most important indicator of this situation.

Individuals with PCOS tend to exhibit insulin resistance (IR) and circulating levels of insulin higher than controls matched to (body mass index (BMI) ( 1 , 2 ). In this sense, in terms of clinical results, BMI follow-up and PCOS clinic follow-up are followed in a correlation in slightly overweight and obese individuals ( 3 , 4 ). In the emergence of obesity, hormone-based pictures and diseases such as many thyroid disorders come to the fore ( 5 ).

Thyroid hormones, which play a key role in metabolism, show their metabolic effects through the hormone insulin. While acting as insulin agonists in muscle tissue, on the contrary, it can act as an antagonist in the liver ( 4 , 6 ). In addition to being required in normal glucose balance, missing or excess thyroid hormone may cause a break that disrupts the balance ( 7 ). Thyroid imbalances have been linked to hyperlipidemia, increased storage fat, weight gain, increased testosterone, and aromatization to estradiol ( 8 ). It has been reported that especially hypothyroidism picture may cause an imbalance with its efficiency in glucose metabolism ( 9 ), so these patients may experience both hypoglycemia and (IR)( 10 ). Hypothyroidism may affect gonadal functions of females and cause a delay in the transition of puberty and monthly cycles ( 11 , 12 ). Based on the clinical studies conducted so far, it is pointed out that insulin and related thyroid hormone changes may affect or worsen PCOS picture by triggering IR ( 4 , 13 , 14 ). Although the prevalence of thyroid-related diseases was higher in women with PCOS than in the general population, there was no clear relationship between IR and thyroid dysfunction. In some studies, it has been reported that there is a decrease in androgen level with hormone supplementation and it is good for PCOS ( 15 ). It has been reported that, following metformin treatment, there is a decrease in thyroid-stimulating hormone (TSH) levels and benefit in PCOS patients ( 16 ).

In the present study, we aimed to evaluate the hormonal alterations through BMI on the relationship between insulin, insulin resistance, and thyroid hormone levels in PCOS groups that we categorized according to BMI levels.

This study is a retrospective clinical analysis study conducted at Istanbul Medistate Hospital, Department of Gynecology and Obstetrics between January 2019 and April 2020.

The presented study was started after ethical approval was obtained (Date: 22/05/2020 - No: 2020/04-14) and approved by the institute review board of Maltepe University.

All PCOS patients were analyzed in two groups as normal weight and obese according to their BMI values that the demographic and clinical data of the patients are given in Table-1 in detail. Age factor did not differ between groups (29.8±6 vs 31±7.2; p=0.345). There was no significant difference in terms of chronic renal failure, diabetes mellitus, cigarette, hypertension, and hyperlipidemia (p>0.05). There was no laboratory sign for both groups in terms of systemic disorders in both groups. As given in Table-2, the only parameter that showed a difference was fasting glucose. In hormone tests, insulin (14.2±6.8 vs 14.8±8; p=0.688), thyroxine (T4) (1.2±0.5 vs 1.2±0.4), TSH (1.9±1.2 vs 1.8±0.9; p=0.848) and HOMA- IR (3.1±1.4 vs 3.4±1.8; p=0.344) levels did not differ for BMI groups (p>0.05). Because there was no difference in laboratory comparison for any parameter, we could not perform multivariate analysis for further investigations in terms of BMI factor. In the hematological analysis, we did not see significant alteration for groups. Mean platelet volume (MPV) and Platelet Distribution Width (PDW), known as inflammatory indicator parameters as reported in recent researches, were also similar in both groups.

The present study analyzed the hormonal alterations through BMI on the relationship between insulin, IR, and thyroid hormone levels in PCOS. In our study, we did not observe any difference between both thyroid and IR in patients who were grouped according to BMI to understand the connection between obesity, diabetes and PCOS. Our findings suggest that PCOS and obesity may be directly related to hormonal interaction rather than adipose tissue.

Recent articles are published about the higher risk of developing coronary artery disease in individuals affected by thyroid disease (19). Tagliaferri et al. showed that thyroid hormone variations or imbalances can have effects on the reproductive endocrine system and metabolic characteristics. In their study, they found a direct significant relationship between TSH and fasting glucose level, but they could not provide sufficient explanation because few studies are showing its effect on glycemic levels ( 3 ). Ganle et al could not find any correlation between TSH and glycemia in their study on thyroid function in PCOS (23). However, Mouradian and Abourizk reported a predisposition to hypoglycemia attacks in patients with PCOS and diabetic concomitant thyroid dysfunction (24). In our study, patients with PCOS did not have diabetes and fasting glycemic levels were within the normal range.

Tagliaferri et al. showed a link between thyroid function and glucose and insulin metabolism in the PCOS group, consistent with the study by Celik and colleagues (32). In particular, they claimed that thyroid hormones may have a role in modulating glucose-stimulated insulin secretion in PCOS. They found significantly higher fasting insulin values in obese PCOS patients compared to those with normal thyroid values. Celik et al. stated that women with PCOS and subclinical hypothyroidism showed higher fasting insulin compared to controls. However, they have not yet clearly clarified whether the increase of TSH in PCOS may be a cause or a consequence of IR. This undisclosed point is that IR is a particularly interesting point because of its role in the pathophysiology of PCOS. Maratou et al. and Lupoli et al. suggested in their study that there was IR due to decreased intracellular glucose use, decreased glucose oxidation, and glycogen synthesis. In several reports, TSH normalization was achieved with the treatment of IR, and regression was shown in the PCOS clinic with thyroid treatment. While Koritschoner et al. reported that treatment with thyroid hormones increased insulin sensitivity and decreased hyperglycemia and hyper insulinemia in their study in rodents, Torrance et al. stated that thyroid hormones decrease adipose tissue mass and improve IR. In our study, we could not find any statistical relationship between thyroid function and metabolic, clinical, or hormonal parameters under evaluation in the normal weight and obese PCOS patient group. Only in overweight PCOS patients, fasting blood glucose meeting may have played a role in the effect of excess body weight.

The study had some limitations due to be a retrospective analysis. First, we could not follow the patients’ data for understanding the clinical side of PCOS and its hormonal alterations with hormones. Secondly, the study had limited patients to obtain strong statistical outputs. Third, the long-time follow-up results could not be collected for further data prediction.

Our findings suggest that PCOS and obesity may be directly related to hormonal interaction rather than adipose tissue. We could not find any statistical relationship between thyroid function and metabolic, clinical, or hormonal parameters under evaluation in the normal weight and obese PCOS patient group. Only in overweight PCOS, fasting glucose may have played a role in the excess body weight.